Catalogo dei Corsi di studio

Curriculum Vitae

Personal information (ORCID 0000-0002-7028-4251)
Family name, First name: Barone, Eugenio
Date of birth: 16 November 1981
Nationality: Italian
Current position: Associate Professor of Biochemistry
Institution: Department of Biochemical Sciences A. Rossi-Fanelli , Sapienza University of Rome, IT
Address: Piazzale Aldo Moro 5, 00185 Rome, IT
Contacts: eugenio.barone@uniroma1.it; +390649910935

Research Summary
Dysfunction of neurotrophic signaling in the brain is a common pathophysiological mechanism leading to cognitive decline in a number of conditions including ageing, neurodegenerative disorders (Alzheimer disease, AD), genetic disorders (Down syndrome, DS) and metabolic diseases (obesity and type 2diabetes mellitus, T2DM). Insulin and GLP1 signalling act as key regulators for gene expression and cellular metabolism, both events sustaining neuronal activity and synaptic plasticity mechanisms. These neurotrophic signaling also control oxidative metabolism via mitochondrial dynamics, thus protecting neurons against oxidative damage. Actions of insulin and GLP1 in the brains of healthy individuals include central modulation of body metabolism and enhancement or regulation of memory and learning functions. Alterations of brain insulin signalling are early pathogenic events associated with the development of neurodegenerative disorders, while GLP1 and GLP1 mimetics appear promising candidates in overcoming brain insulin signaling dysfunctions. The overarching goal of my laboratory is to use multidisciplinary approaches to clarify defects of neurotrophic signaling during ageing and neurodegeneration. The research work mainly focuses on:
1. Clarifying the role of insulin and GLP1 signaling in modulating brain metabolism, by unraveling how defects these pathways are associated with the development of AD-like pathology;
2. Evaluating the link between dysfunction of neurotrophic signaling and increased cell oxidative damage in the brain;
3. Understanding the impact of metabolic disease (type 2 diabetes mellitus/obesity) on AD and DS neuropathology;
4. Evaluating the content of plasma-resident neuronal-derived extracellular vescicles (nEVs) isolated from AD and DS subjects, to identify biomarkers of insulin signaling alterations in the brain of living subjects;
5. Evaluating the effects of metabolic drugs in recovering brain functions from AD-like neuropathology.

EDUCATION

07/2017: National Scientific Qualification as Full Professor of Biochemistry (05/E1)
This is a national evaluation made by a Committee nominated by the Italian Ministry of University and Research (MIUR), that has the role to make a selection of the candidates who can eventually apply to an open call for Full Professor.

02/2011: PhD in Neuroscience
Institute of Pharmacology, Catholic University School of Medicine, Rome, IT

12/2006: National Qualification as Pharmacist
Faculty of Pharmacy, University of Calabria, Arcavacata di Rende (CS), IT

05/2006: Master degree in Pharmaceutical Chemistry and Technology (summa cum laude)
Faculty of Pharmacy, University of Calabria, Arcavacata di Rende (CS), IT

07/2000: Secondary School Diploma (100/100)
Scientific Lyceum G. Galilei , Paola (CS), IT

PREVIOUS POSITIONS

10/2016 10/2019: Assistant Professor of Biochemistry
Department of Biochemical Sciences, Sapienza University of Rome, Rome, IT
Dysfunction of neurotrophic signaling contributes to neuronal dysfunction and death in age-related disorders of the nervous system. The overreaching goal of my lab was to clarify the role of brain insulin signaling alterations in Alzheimer Disease and Down Syndrome.

04/2015 12/2018: Associate Researcher
Faculty of Health Sciences, University Autonoma de Chile, Santiago, CL

03/2016 09/2016: PostDoc
Department of Biochemical Sciences, Sapienza University of Rome, Rome, IT
I completed the work started in range of the Marie Curie fellowship

03/2014 03/2016: PostDoc
Department of Biochemical Sciences, Sapienza University of Rome, Rome, IT
Marie Curie Fellow, People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013)
An important contribution to understanding neurotrophic factor signaling was the characterization of biliverdin reductase-A protein. My research work aimed to clarify the role of dysfunctional BVR-A protein in favouring increased oxidative stress levels and brain insulin resistance development in Alzheimer Disease. Data collected during this period were instrumental for the projects currently ongoing in my lab.

01/2012 12/2013: PostDoc
Brain Mind Institute, Swiss Federal Insitute of Technology (EPFL), Lausanne, CH
The topic of my research work was the identification of -secretase associated proteins. I discovered a novel mechanism through which -secretase promotes the inactivation of Cofilin-1 protein, wich impairs actin dynamics within dendritic spines, finally resulting in impaired synaptic strength and plasticity in Alzheimer disease.

02/2011 07/2011: PostDoc
Institute of Pharmacology, Catholic University School of Medicine Rome, IT

01/2010 11/2010: Research Scholar (as part of the PhD Program in Neuroscience)
(a) Department of Biomedical Pharmacology in the Sanders-Brown Center on Aging and
(b) Department of Chemistry, Laboratory of Neurochemistry, University of Kentucky, Lexington, Kentucky, USA.
During my PhD I had the opportunity to join the labs directed by Prof. D. Allan Butterfield and Prof. Elizabeth Head for a joint collaboration for one year. My research work in Butterfield and Head s labs focused on understanding the role of increased oxidative stress levels in mediating protein post-translational modifications in the brain during aging and neurodegenerative disease

11/2007-02/2011: PhD Candidate in Neuroscience
Institute of Pharmacology, Catholic University School of Medicine Rome, IT
My PhD work focused on unravelling the role of the heme oxygenase/biliverdin reductase system in the free radical-induced cell stress response

09/2006 10/2007: Research Fellow
Institute of Pharmacology, Catholic University School of Medicine, Rome, IT
05/2006 05/2006: Visiting student
Institute of Pathology, Catholic University School of Medicine, Rome, IT

01/2004 06/2004: Visiting student (ERASMUS Project)
Faculté de Pharmacie, Universitè Paris Descartes, Paris, FR

TEACHING ACTIVITIES

The following courses at the Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy:

2018 present: Professor of Biochemistry, Degree in Audioprothesic Techniques
2018 present: Professor of Biochemistry, Degree in Audiometric Techniques
2017 present: Professor of Biochemistry, Degree in Nursing
2016 present: Professor of Biochemistry, Degree in Medicine
2016 present: Professor of Biochemistry, Residency in Neurology

INSTITUTIONAL RESPONSIBILITIES

2019-present: Member of the "Daniel Bovet" Neurobiology Research Center
Sapienza University of Rome, IT

2017 present: Faculty member of the PhD Board - PhD in Biochemistry
Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, IT

2016 present: Committee member, Biochemistry course (CCL A)
Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, IT

SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS

03/2014 present: Supervision of 5 Master students, 2 PhD students and 1 PostDoc
Department of Biochemical Sciences, Sapienza University of Rome, Rome, IT

01/2012 01/2014: Supervision of 2 PhD students,
Brain Mind Institute, Swiss Federal Institute of Technology (EPFL), Lausanne, CH

SCIENTIFIC ACTIVITY

2020: Nominated Associate Editor for Frontiers in Neuroscience

2019: Nominated official consultant to Bio-Rad Laboratories

2019: Invited speaker during the Opportunità di finanziamento per la ricerca nell'ambito delle Neuroscienze .
An event organized by Daniel Bovet Neurobiology Research Center (CRiN) to present European grants opportunities. Sapienza University of Rome, 18 October, 2019. Rome, IT

2019-2020: Guest Editor for Antioxidants journal.
Special Issue: Oxidative stress and neurodegenerative disorders

2019: Reviewer for the National Science Centre in Poland

2019: Organizer and Chair of the Symposium: Metabolic defects in Down syndrome: from periphery to the brain.
3rd International Meeting of the Trisomy 21 Research Society, Barcelona, Spain, 5-9 June, 2019.
Speakers:
Dr. Maria Chiara Pelleri (University of Bologna, IT): Plasma and urinary metabolomic profiles of children with Down syndrome.
Dr. Aurelie Ledreux (University of Denver, USA): Exosome biomarkers reflecting brain changes in DS with AD.
Dr. Kelly Sullivan (U Colorado, USA): Trisomy 21 drives production of neurotoxic tryptophan catabolites via the interferon-inducible kynurenine pathway.

2018-2019: Topic Editor for Frontiers in Neuroscience
Research topic: Brain insulin resistance in neurodevelopment and neurodegenerative diseases: mind the gap!

Since 2018: Organizer and Chair of a series of seminars for the PhD School in Biochemistry and for Daniel Bovet Neurobiology Research Center at Sapienza University of Rome
March 15, 2018, Prof. Joao Duarte (Department of Experimental Medical Science & Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden): Alterations of brain energy metabolism in insulin resistant diabetes.
May 10, 2018, Prof. Patrick Fraering (Campus Biotech Innovation Park & Foundation Eclosion, Geneva, Switzerland): The Emerging Gamma-Secretase Interactome and its Implication in the Pathogenesis of Alzheimer s Disease.
July 5, 2019, Dr. Bindu Diana Paul (The Solomon H. Snyder Dept. of Neuroscience Johns Hopkins University School of Medicine, Baltimore, USA): Bilirubin links heme metabolism to neuroprotection by scavenging superoxide.

Since 2018: Member of the Editorial Board of The Open Pharmacology Journal

2017: Organizer and Chair of the Symposium: La malattia di Alzheimer, conoscerla per affrontarla. Sala consiliare del Comune di Paola (Complesso Sant'Agostino), October 11, 2017. Paola (CS), IT.
Speakers:
Prof. Patrizia Mecocci (University of Perugia-Santa Maria della Misericordia Hospital, Perugia, IT). Sviluppo clinico della malattia di Alzheimer e le Possibilità Terapeutiche Disponibili
Prof. Amalia Bruni (Centro Regionale di Neurogenetica, Lamezia Terme, Azienda Sanitaria Provinciale di Catanzaro, IT). Le cause genetiche della Malattia di Alzheimer
Prof. Marzia Perluigi (Sapienza University of Rome, IT). Le nuove frontiere della ricerca scientifica. A che punto siamo?

Since 2017: Reviewer for the Alzheimer s Association Grant Program

Since 2017: Member of the Editorial Board of Memory Disorders: Research and Clinical Practice

2016-2019: Member of the SfRBM External Marketing/PR Committee
Society for Redox Biology and Medicine

Since 2016: Member of the Editorial Board of Austin Aging Research

2014: Guest Editor for Current Alzheimer Research
Thematic Issue entitled "Oxidative stress and Alzheimer disease: where do we stand?

Since 2013: Member of the Editorial Board of Neural Regeneration Research

Since 2012: Young European Assessor, Italian Medicines Agency (AIFA)

2010: Translation from English to Italian of the Chapter 60 of Special Aspects of Geriatric Pharmacology - Basic & Clinical Pharmacology . B.G. Katzung (ed.), 11th America Edition, Lange Med. Books, McGraw-Hill, New York.

Since 2008: Ad hoc reviewer per Lipids, Experimental Gerontology, Biochemical Pharmacology, Neurochemical Research, BBA General Subjects, Proteomics Clinical Application, Neural Regeneration Research, Advances in Alzheimer s Disease, Advances in Aging Research, BRAIN, FRBM, Neurobiology of Disease, Cellular Physiology and Biochemistry, Journal of Alzheimer s Disease, Diabetes, Neuroscience, Scientific Reports, Archives of Biochemistry, BBA Molecular Basis of disease, Scientific Reports, FASEB Journal, PNAS

FELLOWSHIPS

03/2014 02/2016: Marie Curie Fellowship, funded by the European Union's Seventh Framework Programme (FP7/2007-2013) (rating 93.50/100, excellent)
Department of Biochemical Sciences, Sapienza University of Rome, Rome, IT

12/2010 07/2011: Funded by Istituto Toniolo di Studi Superiori .
Institute of Pharmacology, Catholic University School of Medicine, Rome, IT

06/2010 11/2010: Funded by the Society for Free Radical Biology and Medicine
Department of Chemistry, Lab of Neurochemistry (directed by Prof. D. Allan Butterfield), University of Kentucky, Lexington (KY), USA

01/2010 12/2010: Funded by the Italian Society of Pharmacology
Department of Chemistry, Lab of Neurochemistry (directed by Prof. D. Allan Butterfield), University of Kentucky, Lexington (KY), USA

01/ 2010 12/ 2010: Funded by Regione Calabria, for Master and Ph.D. training.
Department of Chemistry, Lab of Neurochemistry (directed by Prof. D. Allan Butterfield), University of Kentucky, Lexington (KY), USA

09/ 2006 10/2007: Funded by Istituto Toniolo di Studi Superiori .
Institute of Pharmacology, Catholic University School of Medicine, Rome, IT

01/2004-06/2004: Funded by University of Calabria for the ERASMUS Project
Faculté de Pharmacie, Universitè Paris Descartes (Paris V) Paris, FR

AWARDS

06/2018: SFRRI 2018 Best Poster Award
Society for Free Radical Research International Conference, Lisbon, PT

06/2017: T21RS Travel Award
Trisomy 21 Research Society Conference, Chicago (IL), USA

06/2017: AAIC Travel Fellowship
Alzheimer Association International Conference 2017, London, UK

11/2016: SFRBM travel Award
Society for Redox Biology and Medicine Conference, San Francisco (CA), USA

11/2015: SFRBM travel Award
Society for Redox Biology and Medicine Conference, Boston (MA), USA

10/2014: Plenary speaker
Giornata delle Eccellenze meeting by the Italian Ministry of Education (MIUR), Lucca, IT

06/2013: EPHAR Fellowship Award
Federation of the European Pharmacological Society, 11th Summer School of Neuroscience, Catania, IT

10/2010: Selected among the best young talents at the Catholic University School of Medicine, Rome, Italy, to participate at the Festival of Young Talents promoted by the Ministry of Youth

10/2009: Award for the best Poster presented by a young investigator.
34th National Congress of the Italian Society of Pharmacology

MEMBERSHIPS OF SCIENTIFIC SOCIETIES

European Association for the Study of Diabetes (EASD),
European Society for Neurochemistry (ESN)
International Society of Neurochemistry (ISN)
International Society to Advance Alzheimer's Research and Treatment (ISTAART),
Trisomy21 Research Society (T21RS)
Society for Redox Biology and Medicine (SfRBM)
Italian Society of Biochemistry (SIB)

INVITED PRESENTATIONS

2020: Alzheimer Association International Conference (AAIC). Loss of biliverdin reductase-A (BVR-A) impairs beneficial effects of CNS insulin on brain energy metabolism favoring the development of Alzheimer's disease (AD) neuropathology. 24-29 July, 2020. Amsterdam, NL

2020: 11th International Conference on Heme Oxygenase and Related Enzymes: From Physiology to Therapeutics. Biliverdin reductase-A at the crossroad between insulin signaling and energy metabolism: what s new? June 28th to July 1st, 2020, Los Angeles (CL), USA [postponed due to COVID19 pandemic]

2019: Invited Seminar for the PhD School in Morphogenesis & Tissue Engineering. Brain insulin resistance: a route toward the development of Alzheimer Disease pathology. SAIMLAL Department - Histology and Medical Embryology Section, Sapienza University of Rome, 27 November 2019, Rome, IT

2019: III Convegno Nazionale, Sindrome di Down, dalla diagnosi alla terapia: Recenti Progressi negli approcci terapeutici alla Sindrome di Down. Universita di Napoli Federico II, Scuola di Medicina e Chirurgia, 18-19 Ottobre 2019, Napoli, IT

2019: Istituto Nazionale di Fisica Nucleare (INFN) Nanoscience and Nanotechnology Annual meeting. Neuronal-derived exosomes: a promising tool to identify alterations of brain insulin signaling in Alzheimer disease and Down syndrome. October 17th, 2019, Frascati, (Rome), IT

2019: Trisomy 21 Research Society 3rd International meeting. Reduced Insulin Receptor Levels in Neuronal-Derived Exosomes Highlights Early Alterations of Brain Insulin Signaling in Down Syndrome. June 6-9, 2019. Barcelona, SP

2019: Instituto Gulbekian de Ciencia, Annual Seminars Serie. Biliverdin reductase-A: an emerging regulator of insulin signaling pathway in Alzheimer disease and diabetes. March 28, 2019, Lisbon, PT

2019: The 14th international conference on Alzheimer s and Parkinson s diseases, AD/PD 2019. Loss of biliverdin reductase-a limits the oxidative stress-induced Akt-mediated inhibition of Gsk-3 : a novel molecular mechanism favoring Tau phosphorylation in early stage AD. March 26-31, 2019, Lisbon, PT

2018: The Yellow Seminars, Liver Italian Foundation ONLUS. Impairment of Biliverdin reductase-A as a risk factor for the development of insulin resistance in Alzheimer disease and diabetes. October 26, 2018, Trieste, IT

2018: 54th Annual Meeting of the European Association for the Study of Diabetes (EASD). Biliverdin reductase-A mediates the beneficial effects of intranasal insulin administration in Alzheimer disease: a novel molecular mechanism. October 1-5, 2018, Berlin, DE

2017: 2nd International Meeting of the Trisomy 21 Research Society (T21RS). The early onset of brain insulin resistance in Down Syndrome: a bridge toward the development of Alzheimer-like neuropathology. June 7-11, 2017, Chicago (IL), USA

2017: Society of Italian Pharmacology (SIF) monothematic meeting "Aging Brain: In Search for Better Neurotherapeutics". Biliverdin Reductase-A mediates the beneficial effects of intranasal insulin administration on Alzheimer disease pathology. May 4-5, 2017, Cosenza, IT

2016: Society for Redox Biology and Medicine, 23rd Annual Meeting of the Society for Redox Biology and Medicine. Improvement of BVR-A activity ameliorates brain insulin resistance in Alzheimer disease following intranasal insulin administration. November 16-20, 2016, San Francisco (CA), USA

2016: 9th International Conference on Heme Oxygenase. Biliverdin Reductase-A inactivation promotes brain insulin resistance in Alzheimer disease: a new paradigm. September 14-18, 2016, Prague, CZ

2016: The 2016 Alzheimer s Disease Congress. The impairment of Biliverdin Reductase-A promotes insulin resistance in Alzheimer Disease: a novel mechanism. June 7-9, 2016, London, UK

2015: Society for Redox Biology and Medicine, 22nd Annual Meeting of the Society for Redox Biology and Medicine. Biliverdin Reductase-A Inactivation Promotes Insulin Resistance in Alzheimer Disease: A New Paradigm. November 18-21, 2015, Boston (MA), USA

2012: Ecole Polytechnique Federale de Lausanne (EPFL) Brain Mind Institute Seminar series: The oxidative stress hypothesis of Alzheimer's Disease: new insights into mechanisms of neurodegeneration. December 5th, 2012, Lausanne, CH

2012: Society for Free Radical Reaserch International, 16th SFRRI Biennial Meeting. Biliverdin Reductase-A: a Novel Drug Target for Atorvastatin in a Dog Preclinical Model of Alzheimer Disease. 6-9 September 2012, London, UK

2011: Il Farmaco: dalla Ricerca alla Salute dell Uomo, 35th National Congress of the Italian Society of Pharmacology. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. September 14 17 2011, Bologna, IT

2009: Heme Oxygenases 2009, The 6th International Congress. Bilirubin and nitric oxide: just married and baby s arrivals. September 30-October 4, 2009 Miami Beach (FL), USA

LIST OF GRANTS (PI: PRINCIPAL INVESTIGATOR; I: INVESTIGATOR)

Ongoing

2020 (PI): Jerome Lejeune Foundation, Project ID Cycle 2019b #1887 80.000,00 E
Aberrant insulin signaling contributes to development of Alzheimer disease in Down syndrome: search for novel therapeutic strategies

2020 (PI): Alzheimer s Association, Project ID 2019-AARG-643091 - 150.000,00 Dollars
Unravelling a novel mechanism favoring brain insulin resistance development

2019 (PI): Sapienza University of Rome, Project ID RG11916B87F55459 34.000,00 E Unravelling a novel mechanism favoring brain insulin resistance development and its impact on Alzheimer disease neuropathology

2019 (Co-PI): Bio-Rad Laboratories, study agreement to develop a protocol for interrogation of proteins contained within neuronal-derived extracellular vescicles

2017 (PI): Sapienza University of Rome, Project ID RM11715C77336E99 12.000,00 E
Biliverdin reductase-A impairment mediates the development of insulin resistance in obesity and T2DM: a novel mechanism of action

2019 (I): Sapienza University of Rome (Grandi Attrezzature), Project ID GA118164897F9CB1 - 512.000,00 E
Platform for a precision mass measurement in sequencing of therapeutic proteins (PREMISE

2020 (I): Italian Ministry of Health, Project ID GR-2018-12366381 442.000,00 E
Aberrant protein palmitoylation: a novel biomarker and therapeutic target in Alzheimer s disease

2018 (I): Sapienza University of Rome, Project ID RG1181642744DF59 32.000,00 E
The sweet link between aberrant brain metabolism and cognitive decline: A novel role for altered protein O-GlcNAcylation

Completed

2017 (PI): Banca d Italia n. 12868/17 del 5.1.2017 50.000,00 Euros
Nuove strategie terapeutiche per la prevenzione della malattia di Alzheimer

2015 (PI): Sapienza University of Rome, Project ID C26N15KPNH 2.000,00 Euros
Unravelling the impairment of the HO-1/BVR-A system during the progression of Alzheimer disease: new insights for the role of heme

2015 (Co-PI): Italian Ministry of Education, Universities and Research (MIUR), Project ID RBSI144MTL 170.000,00 Euros
Cross-talk between insulin signalling and oxidative stress in Alzheimer disease: A new paradigm

2014 (PI): Sapienza University of Rome, Project ID C26N1448XN 3.000,00 Euro
The Heme Oxygenase-1/Biliverdin reductase-A system as novel therapeutic target for simvastatin treatment in Alzheimer Disease

2014 (PI): European Union's Seventh Framework Programme (FP7/2007-2013), Project ID 624341 180.000,00 Euro
Biliverdin reductase-a in brain insulin signaling and oxidative stress- mediated neurodegeneration

2016 (I): Sapienza University of Rome, Project ID RG116154C9214D1A 34.000,00 Euros
Brain insulin resistance in age-related cognitive decline: molecular mechanisms and novel therapeutic approaches

2016 (I): Jerome Lejeune Foundation, Project ID 1484 26.000,00 Euros
Intranasal rapamycin administration to prevent Alzheimer-like dementia in Down Syndrome

2015 (I): Sapienza University of Rome, Project ID C26H15JT9X 30.000,00 Euro
Intranasal rapamycin for the treatment of Alzheimer-like dementia in Down Syndrome

2014 (I): Sapienza University of Rome, Project ID C26M14Y7P4 15.000,00 Euro
Alternative methods to animal testing: legal and social, scientific and technological aspects

List of Publications of last 10 years (from the most recent)

1. Sferrazzo G, Di Rosa M, Barone E, Li Volti G, Musso N, Tibullo D, Barbagallo I. Heme Oxygenase-1 in Central Nervous Malignancies. J Clin Med (2020), in press

2. Dierssen M, Fructuoso M, Martinez de Lagran M, Perluigi M, Barone E. Down syndrome is a metabolic disease: altered insulin signaling mediates peripheral and brain dysfunctions. Front Neurosci (2020), in press

3. Tramutola A, Lanzillotta C, Di Domenico F, Head E, Butterfield DA, Perluigi M, Barone E. Brain insulin resistance triggers early onset Alzheimer disease in Down Syndrome. Neurobiol Dis (2020) in press, doi: 10.1016/j.nbd.2020

4. Barchetta I, Ciccarelli G, Barone E, Cimini FA, Ceccarelli V, Bertoccini L, Sentinelli F, Tramutola A, Del Ben M, Angelico F, Baroni MG, Lenzi A, Cavallo MG. Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus. Nutrition, Metabolism and Cardiovascular Diseases (2019) 29: 1087-1094.

5. Di Domenico F, Tramutola A, Barone E, Lanzillotta C, Defever O, Arena A, Zuliani I, Foppoli C, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA and Perluigi M. Restoration of aberrant mTOR signaling by intranasal rapamycin reduces oxidative damage: focus on HNE-modified proteins in a mouse model of Down Syndrome . Redox Biol (2019) in press, doi: 10.1016/j.redox.2019

6. Cimini FA, Arena A, Barchetta I, Tramutola A, Ceccarelli V, Lanzillotta C, Fontana M, Bertoccini L, Leonetti F, Capoccia D, Silecchia G, Di Cristofano G, Chiappetta C, Di Domenico F, Baroni MG, Perluigi M, Cavallo MG, Barone E. Reduced biliverdin reductase-A are associated with early alterations of insulin signalling in obesity. BBA Mol Bas Dis (2019) 1865: 1490-1501.

7. Sharma N, Tramutola A, Lanzillotta C, Arena A, Blarzino C, Cassano T, Butterfield DA, Di Domenico F, Perluigi M, Barone E. Loss of biliverdin reductase-A favors Tau hyper-phosphorylation in Alzheimer s disease. Neurobiol Dis (2018) 125:176-189.

8. Tramutola A, Abate G, Lanzillotta C, Triani F, Barone E, Iavarone F, Vincenzoni F, Castagnola M, Marziano M, Memo M, Garrafa E, Butterfield DA, Perluigi M, Di Domenico F, Uberti D. Protein nitration profile of CD3+ lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection. Free Rad Biol Med (2018) 129: 430-439.

9. Tramutola A, Lanzillotta C, Barone E, Arena A, Zuliani I, Mosca L, Blarzino C, Butterfield DA, Perluigi M, Di Domenico F. Intranasal rapamycin ameliorates Alzheimer-like cognitive decline in a mouse model of Down syndrome. Transl Neurodegener (2018) in press, doi: 10.1186/s40035-018-0133-9.

10. Tramutola A, Triani F, Di Domenico F, Barone E, Cai J, Klein JB, Perluigi M, Butterfield DA. Poly-ubiquitin profile in Alzheimer disease brain. Neurobiol Dis (2018) 118:129-141.

11. Triani F, Tramutola A, Di Domenico F, Sharma N, Butterfield DA, Head E, Perluigi M, Barone E. Biliverdin reductase-A impairment links brain insulin resistance with increased A production in an animal model of aging: Implications for Alzheimer disease. BBA-Molecular Basis of Diseases (2018) 1864: 3181-3194.
Selected to be included in the BBA Collection on Cellular Aging and Senescence in 2019

12. Tramutola A, Sharma N, Barone E, Lanzillotta C, Castellani A, Iavarone F, Vincenzoni F, Castagnola M, Butterfield DA, Cassano T, Perluigi M, Di Domenico F. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. BBA-Molecular Basis of Diseases (2018) 1864: 3309-332.

13. Barone E, Tramutola A, Triani F, Calcagnini S, Di Domenico F, Ripoli C, Gaetani S, Grassi C, Butterfield DA, Cassano T and Perluigi M. Biliverdin reductase-A mediates the beneficial effects of intranasal insulin administration in Alzheimer disease. Molecular Neurobiology (2019) 56: 2922-2943.

14. Lanzillotta C, Tramutola A, Meier S, Schimitt F, Barone E, Perluigi M, Di Domenico F, Abisambra JF. Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models. J Alzheimers Dis (2018) 62:347-359.

15. Barone E, Arena A, Head E, Butterfield DA, Perluigi M. Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism. Free Rad Biol Med (2017) 114:84-93.

16. Barone E, Head E, Butterfield DA, Perluigi M. HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology. Free Rad Biol Med (2017) 111:262-269.

17. Tramutola A, Arena A, Cini C, Butterfield DA, Barone E. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer s disease pathology. Expert Rev Neurother (2017) 17: 59-75.

18. Tramutola A, Di Domenico F, Barone E, Giorgi A, Di Francesco L, Schininà E, Coccia R, Arena A, Head E, Butterfield DA, Perluigi M. Poly-Ubiquitinylation Profile in Down Syndrome Brain before and after the Development of Alzheimer Neuropathology. Antioxid Redox Signal (2016) 26: 280-298.

19. Di Domenico F, Barone E, Perluigi M, Butterfield DA. The "Triangle of Death" in Alzheimer Disease Brain: The Aberrant Cross Talk Among Energy Metabolism, mTOR Signaling and Protein Homeostasis Revealed by Redox Proteomics. Antioxid Redox Signal (2016) 26: 364-387.

20. Perluigi M, Barone E, Di Domenico F, Butterfield DA. Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways. BBA Molecular basis of Disease (2016) 1862: 1871-1882.

21. Tramutola A, Pupo G, Di Domenico F, Barone E, Arena A, Lanzillotta C, Broekaart D, Blarzino C, Head E, Butterfield DA and Perluigi M. Activation of p53 in down syndrome and in the ts65dn mouse brain is associated with a pro-apoptotic phenotype. J Alzheimer Dis (2016) 52: 359-371.

22. Barone E, Di Domenico F, Cassano T, Arena A, Tramutola A, Lavecchia MA, Coccia R, Butterfield DA, Perluigi M. Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm. Free Rad Biol Med (2016) 91: 127-142.

23. Tramutola A, Di Domenico F, Barone E, Perluigi M, Butterfield DA. It s all about U(biquitin): Role of the altered ubiquitin proteasome system and UCHL1 in Alzheimer disease. Oxidative Medicine and Cellular Longevity (2016) 2016: 2756068. doi: 10.1155/2016/2756068.

24. Tramutola A, Lanzillotta C, Arena A, Barone E, Perluigi M and Di Domenico F. Increased mTOR signaling contributes to the accumulation of protein oxidative damage in a mouse model of Down syndrome. Neurodegenerative Dis (2016) 16: 62-68.

25. Barone E. Oxidative stress and Alzheimer disease: where do we stand? Curr Alz Res (2016) 13:108-111.

26. Barone E, Cenini G, Di Domenico F, Noel T, Wang C, Perluigi M, St Clair DK, Butterfield DA. Basal brain oxidative and nitrative stress levels are finely regulated by the interplay between superoxide dismutase 2 and p53. J Neurosci Res (2015) 93: 1728-1739.

27. Barone E and Butterfield DA. Insulin Resistance in Alzheimer Disease: Is Heme Oxygenase-1 an Achille's Heel? Neurobiol Dis (2015) 84: 69-77.

28. Di Domenico F, Gilda Pupo, Mancuso C, Barone E, Paolini F, Arena A, Blarzino C, Frederick A. Schmitt, Head E, Butterfield DA and Perluigi M. Bach1 overexpression in Down syndrome correlates with the alteration of the HO-1/BVR-A system: insights for transition to Alzheimer Disease. J Alzheimers Dis (2014) 44:1107-1120.

29. Barone E, Mosser S, Fraering PC. Inactivation of brain Cofilin-1 by age, Alzheimer s disease and -secretase. BBA Molecular basis of Disease (2014) 1842: 2500-2509.

30. Di Domenico F*, Barone E*, Perluigi M, Butterfield DA. Antioxidant Strategy to Reduce Free Radical Species in Alzheimer Disease: An Update. Expert Rev Neurother (2015)15:19-40.
*equally contributed

31. Butterfield DA, Di Domenico F and Barone E. Elevated Risk of Type 2 Diabetes for Development of Alzheimer Disease: a Key Role for Oxidative Stress in Brain. BBA Molecular basis of Disease (2014) 1842: 1693-1706.

32. Perluigi M, Pupo G, Tramutola a, Cini C, Coccia R, Barone E, Head E, Butterfield DA, Di Domenico F. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain. BBA Molecular basis of Disease (2014) 1842: 1144-1153.

33. Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol (2014) 88: 605-616.

34. Barone E, Di Domenico F, Mancuso C, Butterfield DA. The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: It's time for reconciliation. Neurobiol Dis (2014) 62: 144-159.

35. Di Domenico F, Perluigi M, Barone E. Biliverdin Reductase-A correlates with inducible Nitric Oxide Synthase in atorvastatin-treated aged canine brain: implications for Alzheimer Disease. Neural Regeneration Research (2013) 8: 1925-1937.

36. Trombino S, Cassano R, Ferrarelli T, Barone E, Picci N, Mancuso C. Trans-ferulic acid-based solid lipid nanoparticles and their antioxidant effect in rat brain microsomes. Colloids and Surfaces B: Biointerfaces (2013) 109:273 279.

37. Fiorini A, Sultana R, Barone E, Cenini G, Perluigi M, Mancuso C, Cai J, Klein JB, St. Clair D, Butterfield DA. Lack of p53 Affects the Expression of Several Brain Mitochondrial Proteins: Insights from Proteomics into Important Pathways Regulated by p53. PlosOne (2012) 7: e49846.

38. Di Domenico F, Barone E, Mancuso C, Perluigi M, Cocciolo A, Mecocci P, Butterfield DA, Coccia R. HO-1/BVR-A system analysis in plasma from pAD and MCI subjects: a potential biochemical marker for the prediction of the disease. J Alzheimers Dis (2012) 32:277-289.

39. Mancuso C, Barone E, Guido P, Miceli F, Di Domenico F, Perluigi M, Santangelo R, Preziosi P. Inhibition of lipid peroxidation and protein oxidation by endogenous and exogenous antioxidants in rat brain microsomes in vitro. Neurosci Lett (2012) 518:101-105.

40. Barone E, Di Domenico F, Sultana R, Coccia R, Mancuso C, Perluigi M, Butterfield DA. Heme Oxygenase-1 Post-translational Modifications in the Brain of Subjects with Alzheimer Disease and Mild Cognitive Impairment. Free Radical Biol Med (2012) 52:2292-2301.

41. Di Domenico F, Casalena G, Jia J, Sultana R, Barone E, Cai J, Pierce WM, Cini C, Mancuso C, Perluigi M, Davis CM, Alkayed NJ and Butterfield DA. Sex differences in brain proteomes of neuron-specific Stat3-null mice after cerebral ischemia/reperfusion. J Neurochem (2012) 121:680-692.

42. Di Domenico F, Sultana R, Andrew Ferree, Katelyn Smith, Barone E, Perluigi M, Coccia R, Pierce W, CaJi, Mancuso C, Squillace R, Wiengele M, Dalle-Donne I, Wolozin B and Butterfield DA. Redox Proteomics Analyses of the Influence of Co-expression of Wild Type or Mutated LRRK2 and Tau on C. elegans Protein Expression and Oxidative Modification: Relevance to Parkinson Disease. Antioxid Redox Signal (2012) 17:1490-506.

43. Barone E, Cenini G, Sultana R, Di Domenico F, Ada Fiorini, Perluigi M, Teresa Noel, Chi Wang, Mancuso C, Daret K. St. Clair, and Butterfield DA. Lack of p53 Decreases Basal Oxidative Stress Levels in the Brain through Up-Regulation of Thioredoxin-1, Biliverdin Reductase-A, Manganese Superoxide Dismutase and Nuclear Factor-kappa B. Antioxid Redox Signal (2012) 16:1407-1420.

44. Mancuso C, Siciliano R, Barone E and Preziosi P. Natural substances and Alzheimer s disease: from preclinical studies to evidence-based medicine. BBA Molecular basis of Disease (2012) 1822:616-624.

45. Barone E, Mancuso C, Di Domenico F, Sultana R, M. Paul Murphy, Head E, Butterfield DA. Biliverdin Reductase-A: a Novel Drug Target for Atorvastatin in a Dog Preclinical Model of Alzheimer Disease. J Neurochem (2012) 120: 135-146.
Editor choice, commented by Anja Schneider and Mikael Simons in the same issue.

46. Cenini G, Dowling ALS, Beckett TL, Barone E, Mancuso C, Murphy MP, LeVine III H, Schmitt FA, Butterfield DA, Head E. Association between frontal cortex oxidative damage and beta-amyloid neuropathology as a function of age in Down syndrome. BBA Molecular basis of Disease (2011) 1822:130-138.

47. Sarah B. Martin, Cenini G, Barone E, Amy L.S. Dowling, Mancuso C, Butterfield DA, M. Paul Murphy, Head E. Coenzyme Q10 and cognition in atorvastatin treated dogs. Neurosci Lett (2011) 501:92-95.

48. Mancuso C, Siciliano R, Barone E, Butterfield DA and Preziosi P. Pharmacologists and Alzheimer disease therapy: To boldly go where no scientist has gone before. Exp Opin Inv Drug (2011) 20:1243-1261.

49. Butterfield DA, Barone E, Di Domenico F, Cenini G, Sultana R, Murphy MP, Mancuso C and Head E. Atorvastatin Treatment in a Dog Preclinical Model of Alzheimer Disease Leads to Up-regulation of Heme Oxygenase-1 and Is Associated with Reduced Oxidative Stress in Brain. Int J Neuropsychoph (2012) 15: 981-987.

50. Butterfield DA, Barone E and Mancuso C. Cholesterol-independent neuroprotective and neurotoxic activities of statins: perspective for statin use in Alzheimer disease and other age-related neurodegenerative disorders. Pharmacol Res (2011) 64: 180-186.

51. Siciliano R*, Barone E*, Calabrese V, Vincenzo Rispoli, Butterfield DA and Mancuso C. Experimental research on nitric oxide and therapy of Alzheimer disease: a challenging bridge. CNS Neurol Disord-DR (2011) 10:766-776.
*equally contributed

52. Di Domenico F, Sultana R, Barone E, Perluigi M, Mancuso C, Cini C, Cai J, Pierce WM and Butterfield DA. Quantitative phosphoproteomics analysis of hippocampus brain region of Alzheimer Disease patients: Implication of aberrant phosphorylation pathways in the progression of the disease. J Proteomics (2011) 74:1091-1103.

53. Barone E, Di Domenico F, Cenini G, Sultana R, Coccia R, Preziosi P, Perluigi M, Mancuso C, Butterfield DA. Oxidative and Nitrosative Modifications of Biliverdin Reductase-A in the Brain of Subjects with Alzheimer Disease and Amnestic Mild Cognitive Impairment. J Alzheimers Dis (2011) 25:623-633.

54. Barone E, Di Domenico F, Cenini G, Sultana R, Cini C, Preziosi P, Perluigi M, Mancuso C, Butterfield DA. Biliverdin Reductase-A Protein Levels and Activity in the Brains of Subjects with Alzheimer Disease and Mild Cognitive Impairment. BBA Molecular Basis of Disease (2011) 1812: 480-487.

55. Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, Murphy MP, Head E, Butterfield DA. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res (2011) 63: 172-180.

56. Mancuso C, Siciliano R and Barone E. Curcumin and Alzheimer disease: this marriage is not to be performed. J Biol Chem (2011) 286: le(3)

57. Fetoni AR, Mancuso C, Eramo SL, Ralli M, Piacentini R, Barone E, Paludetti G, Troiani D. In vivo protective effect of ferulic acid against noise-induced hearing loss in the guinea-pig. Neuroscience (2010) 169: 1575-1588.

58. Cassano R, Trombino S, Ferrarelli T, Barone E, Arena V, Mancuso C, Picci N. Synthesis, characterization and antinflammatory activity of diclofenac-bound cotton fibers. Biomacromolecules (2010) 11: 1716-1720.

59. Errico S, Shohreh R, Barone E, Pusateri A, Mores N, Mancuso C. Heme oxygenase-derived carbon monoxide modulates gonadotropin-releasing hormone release in immortalized hypothalamic neurons. Neurosci Lett (2010) 471: 175-178.

60. Mancuso C, Barone E. The Heme Oxygenase/Biliverdin Reductase Pathway in Drug Research and Development. Curr Drug Metab (2009) 10: 579-594.

61. Mancuso C, Barone E. No therapeutic effect of dietary omega-3 fatty acid and curcumin in dementia and Alzheimer s disease. J Neurosci, eLetter ID jneuro_el; 21841.

62. Mancuso C, Barone E. Therapeutic use of tea derivatives: all that glitters is not gold. Blood (2009) 114: 2359-2360.

63. Mancuso C, Barone E. Curcumin in clinical practice: myth or reality? Trends Pharmacol Sci (2009) 30: 333-334.

64. Barone E, Trombino S, Cassano R, Sgambato A, De Paola B, Di Stasio E, Picci N, Preziosi P, Mancuso C. Characterization of the s-denitrosylating activity of bilirubin. J Cell Mol Med (2009) 13: 2365-2375.

65. Calabrese V, Cornelius C, Mancuso C, Barone E, Calafato S, Bates T, Rizzarelli E, Dinkova Kostova AT. Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. Front Biosci (2009) 14: 376-97.

66. Barone E, Calabrese V and Mancuso C. Ferulic acid and its therapeutic potential as a hormetin for age-related diseases. Biogerontology (2009) 10: 97-108

67. Mores N, Errico S, Pusateri A, Barone E, Mancuso C. Heme oxygenase expression and activity in immortalized hypothalamic neurons GT1-7. Neurosci Lett (2008) 44: 106-108.

68. Palozza P, Barone E, Mancuso C, Picci N. The protective role of carotenoids against 7-keto-cholesterol formation in solution. Mol Cell Biochem (2008) 309: 61-68.